Sirio Pharma, a contract development and manufacturing organization (CDMO) for the nutraceuticals industry, announced its plans to construct a new production site in Chonburi, Thailand.

After seeing record revenues in 2023, and a 42.86% year-over-year revenue rise in May 2024, Sirio began plans to build its first manufacturing plant in Asia outside of China. The integrated site in Thailand will be Sirio’s eighth facility worldwide, complementing a facility in the E.U., two in the U.S., and four large-scale production sites in China.

Sirio’s board approved a potential total investment of up to $40 million for the project. The new site will feature gummy production facilities and automatic packaging lines for nutraceutical dose forms.

“We have invested in a new multipurpose nutraceutical plant in Thailand to meet the needs of our customers in Southeast Asia,” said Alex Du, general manager of Asia Pacific BU at Sirio Pharma. “In recent years, this has been one of the fastest-growing regions, and we can better serve our customers here with local resources.

“Our global strategy is to support international customers with local production resources in key markets. With our eighth site, this provides even greater flexibility in resources and options for local manufacturing across different regions.”

Sirio will also open a new office in Singapore’s central business district later this month as part of efforts to increase regional customer  and trade association partnering. The proposed new project is pending regulatory review, and a construction start date and more details are expected this year.